- Home
- SLGB vs SNTI Comparison
SLGB vs SNTI Comparison
Compare SLGB & SNTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SLGB | SNTI |
|---|---|---|
| Founded | 2017 | 2016 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Integrated Freight & Logistics | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.1M | 29.8M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | SLGB | SNTI |
|---|---|---|
| Price | $0.50 | $0.95 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 163.1K | ★ 181.8K |
| Earning Date | 05-16-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 77.31 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $29.95 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.41 | $0.77 |
| 52 Week High | $6.02 | $3.88 |
Technical Indicators
Market Signals| Indicator | SLGB | SNTI |
|---|---|---|
| Relative Strength Index (RSI) | 36.66 | 47.55 |
| Support Level | $0.41 | $0.86 |
| Resistance Level | $0.64 | $1.02 |
| Average True Range (ATR) | 0.08 | 0.07 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 34.42 | 40.88 |
Price Performance
Historical ComparisonAbout SLGB Smart Logistics Global Limited Ordinary Shares
Smart Logistics Global Ltd is a contract logistics solution provider in the PRC focusing on industrial raw materials line-haul transportation business. the group focuses on the logistics digital ecosystem through innovation, digital analytics, and infrastructure establishment.
About SNTI Senti Biosciences Inc.
Senti Biosciences Holdings Inc, formerly known as Senti Biosciences Inc, is a clinical-stage biotechnology company developing cell and gene therapies using its gene circuit platform for patients with incurable diseases. Its gene circuits, created from proprietary DNA sequences, are designed to reprogram cells to sense, compute, and respond to cellular environments. Its product candidates are to kill cancer cells, spare healthy cells, increase specificity, and control drug expression. Its candidate, SENTI-202, is a logic-gated off-the-shelf CAR-NK cell therapy for blood cancers, currently in a Phase 1 clinical trial in the United States and Australia for relapsed or refractory hematological malignancies, including Acute Myeloid Leukemia (AML).